KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationAmortizationCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in CashChange in IntangiblesChange in IntangiblesDivestmentsDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShares IssuedShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Amortization - Deferred ChargesCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Gsk (GSK) Short-Term Debt issuances (2016 - 2026)

Gsk has reported Short-Term Debt issuances over the past 14 years, most recently at $1.6 billion for Q1 2026.

  • For Q1 2026, Short-Term Debt issuances changed N/A year-over-year to $1.6 billion; the TTM value through Mar 2026 reached $1.8 billion, changed N/A, while the annual FY2025 figure was $1.4 billion, 238.65% up from the prior year.
  • Short-Term Debt issuances for Q1 2026 was $1.6 billion at Gsk, up from $710.3 million in the prior quarter.
  • Over five years, Short-Term Debt issuances peaked at $1.6 billion in Q1 2026 and troughed at -$409.7 million in Q1 2024.
  • A 4-year average of $430.4 million and a median of $334.1 million in 2022 define the central range for Short-Term Debt issuances.
  • Biggest five-year swings in Short-Term Debt issuances: surged 4746.07% in 2022 and later soared 847.86% in 2025.
  • Year by year, Short-Term Debt issuances stood at $334.1 million in 2022, then plummeted by 128.43% to -$95.0 million in 2024, then skyrocketed by 847.86% to $710.3 million in 2025, then skyrocketed by 127.0% to $1.6 billion in 2026.
  • Business Quant data shows Short-Term Debt issuances for GSK at $1.6 billion in Q1 2026, $710.3 million in Q4 2025, and -$95.0 million in Q4 2024.